Elevated MICs of susceptible antipseudomonal cephalosporins in non-carbapenemase-producing, carbapenem-resistant pseudomonas aeruginosa: Implications for dose optimization

Gill, C. M.; Aktas, E.; Alfouzan, W.; Bourassa, L.; Brink, A.; Burnham, C. -A. D.; Canton, R.; Carmeli, Y.; Falcone, M.; Kiffer, C.; Marchese, A.; Martinez, O.; Pournaras, S.; Seifert, H.; Thabit, A. K.; Villegas, M. V.; Westblade, L. F.; Nicolau, D. P.; Wille, J.; Rezende, T. T. F.; Cekin, Z.; Malkocoglu, G.; Gijon, D.; Tarakmeh, L. A.; Chu, C. Y.; Opperman, C. J.; Tootla, H. D.; Moodley, C.; Coetzee, J.; Vourli, S.; Dimopoulos, G.; Attallah, D. M.; Tiseo, G.; Leonildi, A.; Giordano, C.; Barnini, S.; Menichetti, F.; Di Pilato, V.; Codda, G.; Vena, A.; Giacobbe, D. R.; Satlin, M.; Cardona, A.; Curtis, L.; Fang, F.; Thomson, G.; Thomson, K.

doi:10.1128/AAC.01204-21

The present study evaluated the in vitro potency of ceftazidime and cefepime among carbapenem-resistant Pseudomonas aeruginosa isolates collected as part of a global surveillance program and assessed the pharmacodynamic implications using previously published population pharmacokinetics. When susceptible, MICs resulted at the high end of distribution for both ceftazidime and cefepime, thus 6 g/day was required to achieve optimal pharmacodynamic profiles. These findings should be considered in the clinic and for the application of CLSI susceptibility breakpoints.

Autori interni:	Gill C. M. Aktas E. Alfouzan W. Bourassa L. Brink A. Burnham C. -A. D. Canton R. Carmeli Y. FALCONE, MARCO Kiffer C. Marchese A. Martinez O. Pournaras S. Seifert H. Thabit A. K. Villegas M. V. Westblade L. F. Nicolau D. P. Wille J. Rezende T. T. F. Cekin Z. Malkocoglu G. Gijon D. Tarakmeh L. A. Chu C. Y. Opperman C. J. Tootla H. D. Moodley C. Coetzee J. Vourli S. Dimopoulos G. Attallah D. M. TISEO, GIUSY Leonildi A. Giordano C. BARNINI, SIMONA MENICHETTI, FRANCESCO Di Pilato V. Codda G. Vena A. Giacobbe D. R. Satlin M. Cardona A. Curtis L. Fang F. Thomson G. Thomson K. mostra contributor esterni nascondi contributor esterni
Autori:	Gill, C. M.; Aktas, E.; Alfouzan, W.; Bourassa, L.; Brink, A.; Burnham, C. -A. D.; Canton, R.; Carmeli, Y.; Falcone, M.; Kiffer, C.; Marchese, A.; Martinez, O.; Pournaras, S.; Seifert, H.; Thabit, A. K.; Villegas, M. V.; Westblade, L. F.; Nicolau, D. P.; Wille, J.; Rezende, T. T. F.; Cekin, Z.; Malkocoglu, G.; Gijon, D.; Tarakmeh, L. A.; Chu, C. Y.; Opperman, C. J.; Tootla, H. D.; Moodley, C.; Coetzee, J.; Vourli, S.; Dimopoulos, G.; Attallah, D. M.; Tiseo, G.; Leonildi, A.; Giordano, C.; Barnini, S.; Menichetti, F.; Di Pilato, V.; Codda, G.; Vena, A.; Giacobbe, D. R.; Satlin, M.; Cardona, A.; Curtis, L.; Fang, F.; Thomson, G.; Thomson, K.
Titolo:	Elevated MICs of susceptible antipseudomonal cephalosporins in non-carbapenemase-producing, carbapenem-resistant pseudomonas aeruginosa: Implications for dose optimization
Anno del prodotto:	2021
Abstract:	The present study evaluated the in vitro potency of ceftazidime and cefepime among carbapenem-resistant Pseudomonas aeruginosa isolates collected as part of a global surveillance program and assessed the pharmacodynamic implications using previously published population pharmacokinetics. When susceptible, MICs resulted at the high end of distribution for both ceftazidime and cefepime, thus 6 g/day was required to achieve optimal pharmacodynamic profiles. These findings should be considered in the clinic and for the application of CLSI susceptibility breakpoints.
Digital Object Identifier (DOI):	10.1128/AAC.01204-21
Appare nelle tipologie:	1.1 Articolo in rivista

File in questo prodotto:

Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

CINECA IRIS Institutional Research Information System

File in questo prodotto: